

Stahl's Illustrated

Index

- ADD-H: Comprehensive Teacher's Rating Scale (ACTeRs), 42
 adenosine triphosphate (ATP), 35
 ADHD Rating Scale, 42, 119
 ADHD Symptom checklist-4 (ADHD-SC4), 42
 adolescents: and comorbidity of substance use disorders with ADHD, 54; and development of executive function, 38; differences between diagnosis and treatment of ADHD in adults and, 58; screening and rating scales for ADHD in, 42. *See also* age; children
 Adult Rating Scale, 43
 adults: comorbidities and ADHD in, 48, 54; differences between diagnosis and treatment of ADHD in children and, 58; and evolution of ADHD symptoms with age, 41; motor hyperactivity in, 13; persistence of ADHD into, 40; and psychosocial therapies for ADHD in, 115; screening and rating scales for ADHD in, 43; and sleep problems in ADHD patients, 53; and use of ADHD medications by agent and formulation, 59. *See also* age
 Adults ADHD Self-Report Scale (ASRS-v1.1), 43, 128
 age: and choice of treatment for ADHD, 65; evolution of ADHD symptoms with, 37–43. *See also* adolescents; adults; children
 alpha 2A agonist, 112
 alpha2A receptor, 22, 24, 26–27, 107–108
 alpha2A receptor (ADRA 2A) gene, 31
 alternative experimental treatments, for ADHD, 114
 amphetamine: brand and generic names of, 60; difference between methylphenidate and, 69; formulations of, 77–78; frequency of use in pediatric and adult ADHD patients, 59; mechanism of action of, 70. *See also* D-amphetamine; D,L-amphetamine
 animal models, of iron deficiency, 34
 anterior cingulate cortex (ACC), 4–5, 11, 14
 anxiety disorders, 29–30, 47–48
 arousal: and deficient NE/DA networks, 18–19; excessive mechanisms of, 20–21; and stress, 21; and treatment of ADHD, 61, 63
 atomoxetine: and arousal levels in prefrontal cortex, 63; formulations of, 94; frequency of use by pediatric and adult ADHD patients, 59; molecular actions of, 95; pharmacological properties of, 100–101; regional effects of, 96; and weak prefrontal NE and DA signals, 98

- attention, and malfunctioning CSTC loops, 5. *See also* inattention; selective attention; sustained attention
- Attention Deficit Disorders Evaluation Scale (ADDES-3), 42
- attention deficit hyperactivity disorder (ADHD): alternative theories on etiology of, 32–36; evolution of symptoms with age, 37–43; impact of genetics in, 31, 33; neurobiology and hypothetical pathophysiology of, 1–15; and neurotransmitters, 9, 16–30. *See also* comorbidity; diagnosis; medications; screening and rating scales; symptoms; treatment
- Attention Deficit/Hyperactivity Disorder Test (ADHDT), 42
- Attention-Deficit Scales for Adults (ADSA), 43
- autism, 47, 114
- behavioral inhibition, 33
- bipolar disorder, 29, 47–48
- brain, and important areas in executive function and motor control, 3. *See also* neurobiology; neurotransmitters; prefrontal cortex
- brain-derived neurotrophic factor (BDNF), 52
- brand names, of ADHD medications, 60
- Brown Attention-Deficit Disorder Scales for Adults (BADDS), 43
- Brown Attention-Deficit Disorder Scales for Children, 42
- bupropion: formulations of, 94; molecular actions of, 95; pharmacological properties of, 102–103; regional effects of, 97
- “burn-out,” and stimulant abuse, 72
- Childhood/Current ADHD Symptom Scale, 43
- children: and comorbidities in ADHD, 47; differences between diagnosis and treatment of ADHD in adults and, 58; and evolution of ADHD symptoms with age, 41; and impact of development on ADHD, 39; motor hyperactivity in, 13; screening and rating scales for ADHD in, 42; and sleep problems in ADHD patients, 53; synaptogenesis in prefrontal cortex and sustained attention in, 38; use of ADHD medications by agent and formulation, 59. *See also* adolescents; age
- clonidine: formulations of, 106; mechanisms of action, 107; and obesity, 51; pharmacological properties of, 108–109
- cognitive function: and deficient arousal networks, 18; definition of normal, 15; and excessive arousal networks, 20; and maladaptive signal-to-noise ratios, 22–27. *See also* executive function
- College ADHD Response Evaluation (CARE), 43
- comorbidity, of ADHD: in adults, 48; in children, 47; and excessive arousal, 21; increase in rates of with age, 39; neurobiology and, 46; and obesity, 49–52; prefrontal cortex and symptoms in, 29; and sleep problems, 30, 47, 53; and substance use disorders, 48, 54; treatment of, 21, 29, 55. *See also* psychiatric syndromes
- compulsivity, and malfunctioning CSTC loops, 5
- concentration, and overlap of symptoms among psychiatric syndromes, 8
- conduct disorder (CD), 29, 47
- Conner's Adult Attention Deficit/Hyperactivity Disorder Rating Scale (CAARS), 43
- Conner's Parent Rating Scale (CPRS), 42
- controlled-release formulations, of stimulants, 78–81
- Copeland Symptom Checklist for Attention Deficit Disorder, 42–43
- cortical-striatal-thalamic-cortical (CSTC) loops, 3–5, 7
- cyclic adenosine monophosphate (cAMP), 23–24
- D-amphetamine, 86–87. *See also* lisdexamfetamine

- dendritic spine, and signal distribution, 23
- depression, 48. *See also* major depressive disorder
- development, impact of on ADHD, 39
- dexmethylphenidate, 59
- dextroamphetamine, 59
- diagnosis, of ADHD: in children/
adolescents versus adults, 58; and
diagnostic symptoms in DSM-IV, 2; and
misdiagnosis of ADHD in sleep problem
cases, 53
- Diagnostic and Statistical Manual of
Mental Disorders IV (DSM-IV), 2
- diet, and hypotheses on etiology of ADHD,
36
- D₄ receptor (DRD 4) and D₅ receptor (DRD
5) genes, 31
- D,L-amphetamine, 88–89
- D,L-methylphenidate, 84–85
- D-methylphenidate, 82–83
- dopamine (DA): and atomoxetine, 98–99;
and baseline neuronal firing, 16;
bupropion and levels of, 97; and chronic
stress, 64; and deficient arousal
networks, 18–19; D1 receptors and
signal-to-noise ratio, 25–27, 62; and
excessive arousal mechanisms, 20; and
phasic neuronal firing in reward centers,
17; regulation of transport and
availability of synaptic, 67; stimulants
and synaptic levels of, 69; stimulants and
amplification of tonic and phasic NE and
DA signals, 74–75; and treatment of
ADHD, 9. *See also* dopamine receptors;
dopamine transporter (DAT);
neurotransmitters
- dopamine beta hydroxylase (DBH) gene,
31
- dopamine receptors, 25–27, 50. *See also*
D₄ receptor (DRD 4) and D₅ receptor
(DRD 5) genes
- dopamine transporter (DAT): amphetamine
as competitive inhibitor of, 69, 70;
bupropion and inhibition of, 97; and
mechanism of action of modafinil, 104;
and mechanism of action of
methylphenidate, 68; and regional
effects of atomoxetine, 96; and
regulation of synaptic DA, 67; stimulants
and amplification of tonic NE and DA
signals, 74
- dopamine transporter (DAT) gene, 31
- dorsolateral prefrontal cortex (DLPFC): and
N-back test, 7; and regulation of
executive function, 5, 9; sustained
attention and malfunctions of, 4, 7, 28.
See also prefrontal cortex
- dosing: and atomoxetine, 101; and
bupropion, 103; and clonidine, 109;
and D-amphetamine, 87; and
D,L-amphetamine, 89; and
D-methylphenidate, 83; and
D,L-methylphenidate, 85; and
guanfacine, 111; and lisdexamfetamine,
91; and modafinil, 105
- drug interactions: and atomoxetine, 101;
and bupropion, 103; and clonidine,
109; and D-amphetamine, 87; and
D,L-amphetamine, 89; and
D-methylphenidate, 83; and
D,L-methylphenidate, 85; and
guanfacine, 111; and lisdexamfetamine,
91; and modafinil, 105
- emotions, and CSTC loops, 5
- environmental oversampling syndrome,
49
- epilepsy, 47
- excessive daytime sleepiness (EDS), 52
- executive function: areas of brain important
in, 3; and CSTC loops, 5; and N-back
test, 6; synaptogenesis in prefrontal
cortex and development of, 38. *See also*
attention; cognitive function
- extended-release formulations, of
stimulants, 77, 82
- fatty acid desaturase 2 (FADS 2), 31
- 5HT transporter (5HTTLPR) gene, 31
- foods and food additives, and etiology of
ADHD, 36
- generalized anxiety disorder (GAD), 30
- generic names, of ADHD medications,
60
- genetics, impact of in ADHD, 31, 33

- guanfacine: and arousal levels in prefrontal cortex, 63; formulations of, 106; mechanism of action, 107; pharmacological properties of, 110–11
- hippocampus, 50
- histamine (HA), 9
- hyperactivity: and clusters of symptoms, 2; evolution of with age, 41; and prefrontal cortex, 28. *See also* motor hyperactivity
- hyperarousal, 20
- hyperpolarization-activated cyclic nucleotide-gated cation channels (HCN channels), 23–25
- hypertension, and clonidine, 108
- hypoarousal, 52
- hypothalamic-pituitary-adrenal axis, 99
- IL-8 (cytokine), 50
- immediate-release formulations, of stimulants, 76–77
- impairment: clusters of symptoms and degree of in ADHD, 2; and treatment of comorbid disorders in ADHD, 55
- impulsivity: and clusters of symptoms, 2; and eating habits, 49; evolution of with age, 41; and malfunctioning CSTC loops, 5; and orbital frontal cortex, 12, 28
- inattention: and clusters of symptoms, 2; evolution of with age, 41; as symptom in different psychiatric disorders, 30. *See also* attention
- individualized treatment plan, 55
- information processing, and CSTC loop, 11. *See also* executive function
- iron deficiency hypothesis, 34, 47
- lactate, 35
- learning disabilities, 47
- lisdexamfetamine: and amplification of tonic NE/DA signals, 74; formulations of, 77, 81; pharmacological properties of, 90–91
- locus coeruleus (LC), 3, 26–27
- long-term potentiation (LTP), 50
- magnesium, 114
- major depressive disorder (MDD), 8, 30, 102. *See also* depression
- mazindol, 52
- medical illness. *See* comorbidity
- medications: brand and generic names of, 60; crossover effects of in obesity and ADHD, 51; frequency of use by agent and formulation for children and adults, 59. *See also* dosing; drug interactions; non-stimulant drugs; side effects; stimulants
- metformin, 51
- methamphetamine, 59
- methylphenidate: brand and generic names of, 60; difference between amphetamine and, 69; formulations of, 74, 76, 79–80; frequency of use in pediatric and adult ADHD patients, 59; mechanism of action of, 68; and obesity, 51. *See also* D-methylphenidate
- modafinil, 94, 104
- mood disorders, and comorbidity with ADHD, 29. *See also* depression
- motor control, 3, 5
- motor hyperactivity, and prefrontal motor cortex, 13. *See also* hyperactivity
- multiple bead system, for controlled-release formulations, 78
- narcolepsy, 8, 30
- nature vs. nurture theory, 33
- N-back test, 6–7
- neurobiology: and comorbidities with ADHD, 46; and hypothetical pathophysiology of ADHD, 1–15. *See also* brain; neurotransmitters
- neuronal and glial energetics hypothesis, 35
- neurotransmitters: and links between obesity and ADHD, 50; role of in hypothetical pathophysiology of ADHD, 9, 16–30. *See also* dopamine (DA); neurobiology; norepinephrine (NE)
- nicotine addiction, 102
- non-stimulant drugs: and alpha 2A agonists, 112; and alternative experimental treatments, 114; brand and generic names of, 60; formulations of,

- 94, 106; overview of, 93; and treatment of oppositional symptoms, 113. *See also* atomoxetine; bupropion; clonidine; guanfacine; modafinil
- norepinephrine (NE): alpha2A receptors and signal-to-noise ratio, 24, 26–27, 62; and atomoxetine, 98–99; and baseline neuronal firing, 16; and chronic stress, 64; and deficient arousal networks, 18–19; and excessive arousal mechanisms, 20; stimulants and amplification of tonic and phasic NE/DA signals, 74–75; stimulants and synaptic levels of, 69. *See also* norepinephrine transporter (NET); neurotransmitters
- norepinephrine dopamine reuptake inhibitor (NDRI), 95
- norepinephrine reuptake inhibitor, 100, 102
- norepinephrine transporter (NET), 68, 74, 96, 99
- nucleus accumbens (NAcc), 5, 17
- nutritional deficiencies, in autism and ADHD, 114. *See also* diet
- O-back variant, of N-back test, 6
- obesity, comorbidity of with ADHD, 49–52
- obstructive sleep apnea, 30
- omega-3-fatty acids, 114
- 1-back variant, of N-back test, 6
- oppositional defiant disorder (ODD), 29, 47
- oppositional symptoms, treatment of ADHD and, 113
- orbital frontal cortex (OFC): and core symptoms of ADHD, 28; impulsive symptoms and impairments of, 4–5, 12; interconnected networks in ADHD and, 14. *See also* prefrontal cortex
- osmotic controlled-release oral delivery system (OROS), 79
- patches, and controlled-release medications, 74, 76, 80
- phasic firing, of DA/NE neurons, 17, 20, 72
- prefrontal cortex: arousal levels and treatment of ADHD, 61, 63; and cognitive function, 15; and comorbid symptoms, 29; core symptoms of ADHD and malfunction of, 4, 28; and interconnected networks in ADHD, 14; and motor hyperactivity, 13; and role of DA and NE in signal-to-noise ratio, 26–27, 62; synaptogenesis in and development of executive function, 38. *See also* dorsolateral prefrontal cortex; orbital frontal cortex
- prevalence: of ADHD in children and adolescents versus adults, 58; of sleep problems in children with ADHD, 53
- primary disorder, and comorbidity of ADHD with substance use disorders, 54
- problem-solving, assessment of with N-back test, 7
- prodrug, 81
- psychiatric syndromes, overlap of symptoms among, 8. *See also* anxiety disorders; comorbidity; conduct disorder; mood disorders; oppositional defiant disorder
- psychosocial therapies, for ADHD, 115
- pulsatile firing, 71
- rating scales. *See* screening and rating scales
- restless leg syndrome, 34, 47
- reward conditioning, and DA pathways in nucleus accumbens, 17
- risk factors, for behavioral inhibition, 33
- screening and rating scales, 42–43, 119–29
- selective attention: and prefrontal cortex, 28; and Stroop task, 10–11. *See also* attention
- selective norepinephrine reuptake inhibitor (NRI), 95
- selective serotonin reuptake inhibitor (SSRI), 68
- serotonin 1B receptor (HTR 1B) gene, 31
- shift work sleep disorder, 30
- side effects: of atomoxetine, 101; of bupropion, 103; of clonidine, 109; of D-amphetamine, 87; of D,L-amphetamine, 89; of

- side effects (*cont.*)
 - D-methylphenidate, 83; of
 - D,L-methylphenidate, 85; of guanfacine, 111; of lisdexamfetamine, 91; of modafinil, 105
- signal-to-noise ratios, and cognitive function, 22–27
- sleep deprivation, 30
- sleep problems, comorbidity of with ADHD, 30, 47, 53
- SNAP-IV Rating Scale – Revised (SNAP-IV-R), 42, 121–25
- SODAS microbeads d-methylphenidate, 76
- spansules, 78
- stimulants: and amplification of tonic and phasic NE and DA signals, 74–75; and controlled-release formulations, 78–81; paradoxical effect of in ADHD patients, 73; pulsatile versus slow/sustained drug delivery and, 71; and regulation of synaptic DA, 67; and sleep problems, 53; and substance abuse, 72, 75. *See also* amphetamine; dexamethylphenidate; dextroamphetamine; lisdexamfetamine; methamphetamine; methylphenidate
- stress: and atomoxetine, 99; and excessive arousal, 21; and treatment of ADHD, 64
- Stroop task, 10–11
- substance abuse: comorbidity of substance use disorders with ADHD, 48, 54; and stimulants, 72, 75, 86
- subsyndromal symptoms, and persistence of ADHD into adulthood, 40
- sustained attention: and N-back test, 6–7; and prefrontal cortex, 28, 38. *See also* attention
- sustained-release formulations, of stimulants, 76–77, 84
- SWAN Rating Scale for ADHD, 42, 126–27
- symptoms, of ADHD: different disorders and similar, 30; and DSM-IV, 2; evolution of with patient age, 37–43; non-stimulant drugs and oppositional, 113; and overlaps among psychiatric syndromes, 8; and prefrontal cortex, 4, 28–29. *See also* attention; hyperactivity; impulsivity
- synaptic protein (SNAP 25) gene, 31
- synaptic pruning, 38
- television programs, 49
- Test of Everyday Attention for Children (TEA-Ch), 42
- Test of Variables of Attention, 43
- time-release beads racemic methylphenidate, 76
- tonic firing, of DA and NE systems, 16–20, 72, 74
- Tourette's syndrome, 34, 47
- transdermal methylphenidate patch, 74, 84, 86
- treatment, of ADHD: age of patient and choice of, 65; alternative experimental forms of, 114; and arousal levels in prefrontal cortex, 61, 63; of comorbidities, 21, 29, 55; and differences between children/adolescents versus adults, 58; overview of issues in, 57–65; for similar symptoms in different psychiatric disorders, 30; and stress, 64. *See also* medications
- TrkB receptor agonists, 52
- tuberomammillary nucleus (TMN), 9
- two-bead system, for controlled-release formulations, 78
- Vanderbilt ADHD Diagnostic Rating Scales, 42
- ventral tegmental area (VTA), 3, 26–27
- vesicular monoamine transporter (VMAT), 67, 70
- vitamin B6, 114
- Wender Utah Rating Scale (WURS), 43, 120
- Werry-Weiss-Peters Activity Rating Scale, 42
- withdrawal, and stimulant abuse, 72
- zinc, 114